MDMA('Ecstasy')-consumption - A survey of psychiatric and medical consequences;MDMA('Ecstasy')-Konsum - Ein Uberblick zu psychiatrischen und medizinischen Folgen

Fortschritte der Neurologie Psychiatrie

Volumn 65, Issue 2, 1997, Pages 49-61

  Thomasius, R ^a,b   Schmolke, M ^a   Kraus, D ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

CONVULSION; DEPERSONALIZATION; DEPRESSION; DRUG ABUSE; HUMAN; PANIC; PARANOIA; REVIEW; ADDICTION; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; NEUROLOGIC EXAMINATION; PSYCHOLOGICAL ASPECT; PSYCHOSIS; SEIZURE;

BRAIN; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROLOGIC EXAMINATION; PSYCHOSES, SUBSTANCE-INDUCED; SEIZURES; SUBSTANCE-RELATED DISORDERS;

EID: 0031063867     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996309     Document Type: Review

References (113)

1. Ali, S. F., C. D. Newport, A. C. Scallet, Z. Binienda, S. A. Ferguson, J. R. Bailey, M. G. Paule, W. Slikker: Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol. Teratol. 15 (1993) 91-96
2. Barrett, P. J., G. T. Taylor: "Ecstasy" ingestion: a case report of severe complications. J. Royal. Soc Med. 86 (1993) 233-234
3. Barren, P. J.: Ecstasy and dantrolene. Br. Med. J. 305 (1992) 1225
4. Battaglia, G., B. P. Brooks, C. Kulsakdinun, E. B. De Souza: Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmac. 149 (1988a) 159-163
5. Battaglia, G., S. Y. Yeh, E. B. De Souza: MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29 (1988b) 269-274
6. Beck, J., P. A. Morgan: Designer drug confusion: a focus on MDMA. J. Drug. Education 16 (3) (1986) 287-302
7. Benazzi, F., M. Mazzoli: Psychiatric illness associated with "ecstasy". Lancet 338 (1991) 1520
8. Brodkin, J., A. Malyala, J. F. Nash: Effect of acute monamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 45 (1993) 647-653
9. Bronson, M. E., W. Jiang, C. R. Clark, I. DeRuiter: Effects of designer drugs on the chicken embryo and 1-day-old-chicken. Brain Res. Bull. 34 (2) (1994) 143-150
10. Brown, C., J. Osterloh: Multiple severe complications from recreational ingestition of MDMA ("Ecstasy"). JAMA 258 (14) (1987) 780-781
11. Bryden, A. A., P. J. N. Rothwell, P. H. O'Reilly: Urinary retention with misuse of "ecstasy". Br. Med. J. 310 (1995) 504
12. Buffum, J., C. Moser: MDMA and human sexual function. J. Psychoact. Drugs 18 (4) (1986) 355-359
13. Bundeskriminalamt (BKA): Rauschgiftjahresbericht 1993. Wiesbaden 1994
14. Bundeskriminalamt (BKA): Rauschgiftjahresbericht 1994. Wiesbaden 1995
15. Bundeszentrale für gesundheitliche Aufklärung: Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland. Köln, Referat 2-25 (1994)
16. Cadier, M. A., J. A. Clarke: Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burns 19 (3) (1993) 239-240
17. Callaway, C. W., M. A. Geyer: Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur. J. Pharmac. 214 (1992) 45-51
18. Callaway, C. W., M. P. Johnson, L. H. Gold, D. E. Nichols, M. A. Geyer: Amphetamine derivates induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology 104 (1991) 293-301
19. Campkin, N. T. A., U. M. Davies: Another death from Ecstasy. J. Royal. Soc. Med. 85 (1992) 61
20. Cassidy, G., C. G. Ballard: Psychiatric sequele of MDMA (ecstasy) and related drugs. Ir. J. Psychol. Med. 11 (3) (1994) 132-133
21. Chadwick, I. S., A. Linsley, A. J. Freemont, B. Doran, P. D. Curry: Ecstasy 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J. Royal. Soc. Med. 84 (1991) 371
22. Colado, M. I., T. K. Murray, A. R. Green: 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol. 108 (1993) 583-589
23. Commins, D. L., G. Vosmer, R. M. Virus, W. L. Woolverton, C. R. Schuster, L. S. Seiden: Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Therap. 241 (1) (1987) 338-345
24. Creighton, F. J., D. L. Black, C. E. Hyde: "Ecstasy" psychosis and flashbacks. Br.J. Psychiatry 159 (1991) 713-715
25. Cuomo, M. J., P. G. Dyment, V. M. Gammino: Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. J. Am. Coll. Health 42 (6) (1994) 271-274
26. Dowling, G. P., E. T. McDonough, R. O. Bost: "Eve" and "Ecstasy" a report of five deaths associated with the use of MDEA and MDMA. JAMA 257 (12) (1987) 1615-1617
27. Downing, J.: The psychological and physiological effects of MDMA on normal volunteers. J. Psychoact. Drugs 18 (4) (1986) 335-340
28. Fahal, I. H., D. F. Sallomi, M. Yaqoob, G. M. Bell: Acute renal failure after ecstasy. Br. Med. J. 305 (1992) 29
29. Finnegan, K. T., L. Calder, J. Clikeman, S. Wei, R. Karler: Effects of 1-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats. Brain. Res. 603 (1993) 134-138
30. Forrest, A. R. W., J. H. Galloway, I. D. Marsh, G. A. Strachan, J. C. Clark: A fatal overdose with 3,4-methylenedioxyamphetamine derivates. Forensic Science International 64 (1994) 57-59
31. Foxcroft, D. R., G. Lowe: Adolescent drinking, smoking and other substance use involvement: links with perceived family life. Journal of Adolescence 18 (1995) 159-177
32. Gehlert, D. R., C. J. Schmidt, L. Wu, W. Lovenberg: Evidence for specific methylenedioxymethamphetamine (ecstasy) binding sites in the rat brain. Eu. J. Pharm. 119 (1985) 135-136
33. Gledhill, J. A., D. F. Moore, D. Bell, J. A. Henry: Subarachnoidal haemorrhage associated with MDMA abuse. J. Neuro. Neurosurg. Psych. 56 (1993) 1036-1037
34. Gold, L. H., C. B. Hubner, G. F. Koob: A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology 99 (1989) 40-47
35. Gorard, D. A., S. E. Davies, M. L. Clark: Misuse of ecstasy. Br. Med. J. 305 (1992) 309
36. Greer, G., R. Tolbert: Subjective reports of the effects of MDMA in a clinical setting. J. Psychoact. Drugs 18 (4) (1986) 319-327
37. Gu, X. F., E. C Azmitia: Integrative transport-mediated release from cytoplasmatic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur. J. Pharmac. 235 (1993) 51-75
38. Hardman, H. F., C. O. Haavik, M. H. Seevers: Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol. Appl. Pharmacol. 25 (1973) 299-309
39. Hayner, G. N., H. McKinney: MDMA the dark side of ecstasy. J. Psychoact. Drugs 18 (4) (1986) 341-347
40. Henry, J. A., K. J. Jeffreys, S. Dawling: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
41. Henry, J. A.: Ecstasy and the dance of death. Br. Med. J. 305 (6844) (1992) 5-6
42. Hiramatsu, M., A. K. Cho: Enatiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29 (3) (1990) 269-275
43. Hooft, P. J., H. P. van de Voorde: Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing. Int. J. Leg. Med. 106 (1994) 328-329
44. Hughes, J. C., M. McCabe, R. J. Evans: Intracranial haemorrhage associated with ingestion of "Ecstasy". Arch. Emergency. Med. 10 (1993) 372-374
45. Hurrelmann, K.: Die Ecstasy-Welle. Von den betäubenden zu den aufputschenden illegalen Drogen? Bielefeld 1995 (Vortragsmanuskript)
46. Insel, T. R., G. Battaglia, J. N. Johannessen, S. Marra, E. B. De Sooza: 3,4-Methylenedioxymethamphetamine ("Ecstasy") destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Therap. 249 (3) (1989) 713-720
47. Institut für Therapieforschung (IFT): Telefonbefragung 1994 zum Konsum und Mißbrauch von illegalen Drogen, alkoholischen Getränken, Medikamenten und Tabakwaren. München 1995
48. Jamin, J.: Verbotene Früchte-Drogenprävention nach Maß. In: Büro für Suchtprävention (Hrsg.): Ecstasy-Prävention des Mißbrauchs. Neuland, Hamburg (1995) 91-105
49. Johnson, M., I. Elayan, G. R. Hanson, L. Foltz, J. W. Gibb, H. K. Lim: Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Therap. 261 (2) (1992) 447-453
50. Kaminer, Y.: Adolescent substance abuse. Plenum, New York, London 1994
51. Kaskey, G. B.: Possible interaction between an MAOI and "Ecstasy". Am. J. Psychiatry 149 (3) (1992) 411-412
52. Keenan, E., M. Gervin, A. Dormann, J. O'Connor: Psychosis and recreational use of MDMA ("Ecstasy"). Ir. J. Psychol. Med. 10 (3) (1993) 162-163
53. Krystal, J. H., L. H. Price: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function? Am. J. Drug. Alcohol. Abuse 18 (3) (1992) 331-341
54. Lehmann, E. D., C. H. Thom, D. N. Croft: Delayed severe rhabdomyolysis after taking "ecstasy". Postgrad. Med. J. 71 (1995) 186 -188
55. Leonardi, E. T. K., E. C. Azmitia: MDMA (Ecstasy) Inhibition of MAO Type A and Type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10 (4) (1994) 231 -238
56. Liester, M. B., C. S. Grob, G. L. Bravo, R. N. Walsh: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J. Nerv. Ment. Dis. 180 (6) (1992) 345-352
57. Manchanda, S., M. J. Connolly: Cerebral infarction in association with Ecstasy abuse. Postgrad. Med. J. 69 (1993) 874-875
58. Marsh, J. C. W., Z. H. Abboudi, F. M. Gibson, J. Scopes, S. Daly, D. F. O'Shaunnessy, A. S. J. Baughan, E. C. Gordon-Smith: Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br. J. Haem. 88 (1994) 281-285
59. Maxwell, D. L., M. I. Polkey, J. A. Henry: Hyponatraemia and catatonic stupor after taking "ecstasy". Br. Med. J. 307 (27) (1993) 1399
60. McCann, U. D., G. A. Ricaurte: Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine ("Ecstasy") in recreational users. J. Clin. Psychopharmacol. 11 (5) (1991) 302-305
61. McCann, U. D., A. Ridenour, Y. Shaham, G. A. Ricaurte: Serotonin neurotoxicity after (±) 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10 (2) (1994) 129-138
62. McCann, U. D., G. A. Ricaurte: MDMA ("Ecstasy") and panic disorder: induction by a single dose. Biol. Psychiatry 32 (1992) 950 -953
63. McGuire, P. K., H. Cope, T. A. Fahy: Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br. J. Psychiatry 165 (1994) 391-395
64. McGuire, P., T. Fahy: Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). Br. Med. J. 302 (23) (1991) 697
65. Measham, F., R. Newcombe, H. Parker: The normalization of recreational drug use amongst young people in North-West-England. Br. J. Sociology 45 (2) (1994) 287-312
66. Miller, D. B., J. P. O'Callaghan: Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57/6J mouse. J. Pharmacol. Exp. Therap. 270 (2) (1994) 752-757
67. Nichols, D. E.: Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens, identification of a new therapeutic class: Entactogens. J. Psychoact. Drugs 18 (4) (1986) 305-313
68. Nimmo, S. M., B. W. Kennedy, W. M. Tullett, A. S. Blyth, J. R. Dougall: Drug-induced hyperthermia. Anaesthesia 48 (1993) 892-895
69. O'Hearn, E., G. Battaglia, E. B. De Souza, M. J. Kuhar, M. E. Mollivier: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neuroscience 8 (8) (1988) 2788-2803
70. Omor, V. E. V., S. F. Ali, R. R. Holson, H. M. Duhart, F. M. Scalzo, W. Slikker: Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol. Teratol. 13 (1991) 13-20
71. O'Neill, D., J. K. Dart: Methylenedioxyamphetamine ("Ecstasy") associated keratopathy. Eye 7 (1993) 805-809
72. Oranje, W. A., P. v. Pol, A. v. d. Wurff, R. N. M. Zeijen, R. W. Stockbrügger, J. W. Arends: XTC-induced hepatitis. Netherlands. J. Med. 44 (1994) 56-59
73. Pallantini, P., D. Mazzi: MDMA (Ecstasy) precipitation of panic disorder. Biol. Psychiatry 32 (1992) 91-95
74. Peroutka, S. J.: Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "Ecstasy") on an under-graduate campus. New Engl. J. Med. 317 (24) (1987) 1542-1543
75. Peroutka, S. J., H. Newman, H. Harris: Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1 (4) (1988) 273-277
76. Pierce, P. A., S. J. Peroutka: Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neuroscience Letters 95 (1988) 208-212
77. Rabes, M.: Ecstasy and Partydrogen. In: Deutsche Hauptstelle gegen die Suchtgefahren (Hrsg.): Jahrbuch Sucht '96. Geesthacht (1995) 161-177
78. Rakete, G., U. Flüsmeier: Ecstasy. Eine explorative Studie zum Konsum und Mißbrauch von Ecstasy. Wiener Zeitschrift für Suchtforschung 3 (1995) 3-15
79. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8 (3) (1993) 201-211
80. Ricaurte, G. A., L. E. DeLanney, I. Irwin, J. W. Langston: Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Research 446 (1988a) 165-168
81. Ricaurte, G. A., L. S. Forno, M. A. Wilson, L. E. DeLanney, I. Irwin, M. E. Molliver, J. W. Langsten: (±)3,4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260 (1) (1988b) 51-55
82. Ricaurte, G. A., A. L. Martello, J. L. Katz, M. B. Martello: Lasting effects of (±)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J. Pharmacol. Exp. Therap. 261 (2) (1992) 616-622
83. Riedlinger, J. E.: The scheduling of MDMA: a pharmacist's perspective. J. Psychoact. Drugs 17 (3) (1985) 167-171
84. Robinson, T. E., E. Castañeda, I. Q, Whishaw: Effects of cortical depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. Neuropsychopharmacology 8 (1) (1993) 77-85
85. Rohrig, T. P., R. W. Prouty: Tissue distribution of methylenedioxymethamphetamine. J. Anal. Tox. 16 (1992) 52-53
86. Rothwell, P. M., R. Grant: Cerebral venous sinus thrombosis induced by "ecstasy". J. Neuro. Neurosurg. Psych. 56 (1993) 1035
87. Satchell, S. C, M. Connaughton: Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br. J. Hospital. Med. 51 (9) (1994) 495
88. Schechter, M. D.: Discriminative Profile of MDMA. Pharmacol. Biochem. Behav. 24 (1986) 1533-1537
89. Schechter, M. D.: Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination. Pharmacol. Biochem. Behav. 38 (1991) 539-544
90. Schechter, M. D.: Serotonergic-dopaminergic mediation of 3,4-methylene-dioxymetharnphetamine (MDMA. "Ecstasy"). Pharmacol. Biochem. Behav. 31 (1989) 817-824
91. Schifano, F., G. Magni: MDMA ("Ecstasy") abuse: psychopathoiogical features and craving for chocolate: a case series. Biol. Psychiatry 36 (11) (1994) 763-767
92. Schifano, F.: Chronic atypical psychosis associated with MDMA ("ecstasy") abuse. Lancet 338 (1991) 1335
93. Schmidt, CJ.: Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J. Pharmacol. Exp. Therap. 240 (1) (1987) 1-6
94. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-Dopa. J. Pharmacol. Exp. Therap. 256 (1) (1991) 230-235
95. Screaton, G. R., H. S. Cairns, M. Sarner, M. Singer, A. Thrasher, S. L. Cohen: Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339 (14) (1992) 677-678
96. Series, H., S. Boeles, E. Dorkins, R. Peveler: Psychiatric complications of "Ecstasy" use. J. Psychopharmacol. 8 (1) (1994) 60-61
97. Shearman, J. D., R. W. Chapman, J. Satsangi, N. G. Ryley: Misuse of ecstasy. Br. Med. J. 305 (1992) 309
98. Shulgin, A. T., D. E. Nichols: Characterization of three new psychotomimetics. In: Stillmann, R. C, R. E. Willette (eds.): The pharmacology of hallucinogens. Pergamon, New York (1978) 74-83
99. Siegel, R. K.: MDMA: Nonmedical use and intoxication. J. Psychoact. Drugs 18 (4) (1986) 349-354
100. Slikker, W., R. R. Holson, S. F. Ali, M. G. Kolta, M. G. Paule, A. C. Scallet, D. E. McMillan, J. R. Bailey, J. S. Hong, F. M. Scalzo: Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10 (1989) 529-542
101. Solowij, N., W. Hall, N. Lee: Recreational MDMA use in Sydney: A profile of "Ecstasy" users and their experiences with the drug. Br.J. Addict. 87 (8) (1992) 1161-1172
102. Steele, T. D., D. E. Nichols, G. K. W. Yim: MDMA transiently alters biogenic amines and metabolites in mouse brain and heart. Pharmacol. Biochem. Behav. 34 (1989) 223-227
103. Stone, D. M., M. Johnson, G. R. Hanson, J. W. Gibb: Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymetnamphetamine. J. Pharmacol. Exp. Then 247 (1) (1988) 79-87
104. Stone, D. M., D. C. Stahl, G. R. Hanson, J. W. Gibb: The effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoaminergic systems in the rat brain. Eur. J. Pharmac. 128 (1986) 41-48
105. Suarez, R. V., R. Riemersma: "Ecstasy" and sudden cardiac death. Am. J. For. Med. Pathology 9 (4) (1988) 339-341
106. Teggin, A. F.: Ecstasy-a dangerous drug. South African Med. J. 81 (1992) 431-432
107. Thomasius, R.: Familiendiagnostik bei Drogenabhängigkeit. Eine Querschnittstudie zur Detailanalyse von Familien mit opiatabhängigen Jungerwachsenen. Springer, Berlin, Heidelberg 1996
108. Wake, D.: Ecstasy overdose: a case study. Intensive. Crit. Care. Nurs. 11 (1995) 6-9
109. Wardle, I.: Ecstasy (MDMA) and Eve (MDEA) in Great Britain. In: Büro für Suchtprävention (Hrsg.): Ecstasy-Prävention des Mißbrauchs. Neuland, Hamburg (1995) 71-80
110. Whitaker-Azmitia, P. M., T. A. Aronson: "Ecstasy" (MDMA)-induced panic. Am. J. Psychiatry 146 (1) (1989) 119
111. Williams, H., D. Meagher, P. Galligan: MDMA ("Ecstasy"); a case of possible drug-induced psychosis. Ir. J. Med. Sci. 162 (2) (1993) 43-44
112. Wodarz, N., J. Boning: "Ecstasy"-induziertes psychotisches Depersonalisationssyndrom. Nervenarzt 64 (1993) 478-480
113. Wright, J. D., L. Pearl: Knowledge and experience of young people regarding drug misuse, 1969-94. Br. Med.J. 310 (6971) (1995) 20-24